Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals reported financial results for Q2 2021, with net revenues at $48.6 million, slightly up from $48.5 million in Q2 2020. The net loss for the quarter was $14.1 million, compared to $12.3 million the previous year. Key highlights include the refiling of the sNDA for Cortrophin® Gel and the ongoing acquisition of Novitium Pharma, expected to close later this year. Despite increased revenues from generic and branded products, operating expenses rose to $64.2 million, impacting profitability. The company held $24.3 million in cash and cash equivalents, with total debt of $205.7 million.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its second quarter 2021 financial results on August 6, 2021. A conference call is scheduled for 8:30 a.m. ET, led by CEO Nikhil Lalwani and CFO Stephen P. Carey. Participants can join via a toll-free number or access the live webcast on the company's website. A replay will be available shortly after the call and for one week. ANI specializes in developing high-quality branded and generic pharmaceuticals, focusing on niche markets like controlled substances and oncology products.
ANI Pharmaceuticals (Nasdaq: ANIP) has re-filed its supplemental new drug application (sNDA) for Cortrophin® Gel with the FDA. CEO Nikhil Lalwani expressed satisfaction with the re-filing process, highlighting the company's extensive efforts to address previous FDA feedback through expert consultations. Cortrophin Gel is considered a key product for ANI, with hopes for market approval to benefit patients. The company specializes in developing and marketing specialty pharmaceuticals, focusing on niche markets.
ANI Pharmaceuticals will present at the Raymond James Human Health Innovation Conference on June 22, 2021, at 12:00 PM Eastern Time. The presentation, featuring CEO Nikhil Lalwani and CFO Stephen Carey, will be available via webcast and archived for 30 days. ANI focuses on delivering high-quality specialty pharmaceuticals, including controlled substances and oncology products. More about the company can be found at www.anipharmaceuticals.com.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced log-in details for its 2021 Virtual Annual Meeting of Stockholders on June 2, 2021, at 10 a.m. Eastern Time. Stockholders of record as of April 26, 2021, can vote and submit questions during the meeting via a provided control number. Participants can log in starting at 9:45 a.m. An annual meeting replay will be available for one year. ANI is a specialty pharmaceutical company focusing on the development and manufacturing of branded and generic prescription pharmaceuticals, including narcotics and oncolytics.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:00 a.m. ET. The presentation will be webcast live and archived for 30 days on the Company's website. ANI is an integrated specialty pharmaceutical company focused on developing and marketing high-quality branded and generic prescription pharmaceuticals, particularly in niche markets.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) reported strong first-quarter results for 2021, achieving net revenues of $54.5 million, up from $49.8 million in Q1 2020. The company is advancing its re-filing for Cortrophin® Gel and plans to acquire Novitium Pharma LLC, a move expected to diversify its portfolio and enhance R&D. Notable FDA submissions for dermatology products from Sandoz Inc. were completed, adding approximately $13.2 million in annual revenues. Despite pandemic-related challenges, ANI's adjusted non-GAAP earnings per share stood at $1.04.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is set to release its first quarter 2021 financial results on May 7, 2021. The announcement will be followed by a conference call hosted by President and CEO Nikhil Lalwani and CFO Stephen P. Carey at 8:30 a.m. ET. Investors can join via a toll-free number or through a live webcast, which will also be available for replay. ANI focuses on developing and marketing high-quality prescription pharmaceuticals, including niche segments such as oncology and controlled substances.
ANI Pharmaceuticals (NASDAQ:ANIP) has acquired the NDAs for OXISTAT® Lotion, VEREGEN® Ointment, Pandel® Cream, and the ANDA for ApexiCon® E Cream from Sandoz Inc. These products generated net revenues of $13.2 million in 2020. The acquisition is funded via borrowings from the company's credit facility. ANI and Sandoz also entered a multi-year manufacturing agreement for the products, which ANI plans to manufacture in-house in the future. This aligns with ANI's strategy of expanding its established brands business.
ANI Pharmaceuticals (NASDAQ: ANIP) reported its business highlights and financial results for Q4 and the full year 2020. Key achievements include a definitive agreement to acquire Novitium Pharma for $163.5 million, expected to enhance earnings within a year. Q4 net revenues increased to $57.3 million, up from $48.0 million in Q4 2019. However, the company reported a GAAP net loss of $3.6 million in Q4 2020, with a diluted loss per share of $0.30. Full-year 2020 revenues were $208.5 million, slightly up from 2019. ANI aims to boost its growth strategy with a focus on Cortrophin and generics.